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Introduction
Phosphoinositides are minor components of cellular mem-
branes but play key regulatory roles in cell physiology (Di Paolo 
and De Camilli, 2006). Their phosphorylated head groups, 
which protrude from the cytosolic leaflet of membranes, bind 
with variable affinity and specificity to proteins located in 
or exposed to the cytosolic space (Lemmon, 2008). Through 
these interactions, the heterogeneous distribution of the seven 
phosphoinositides in different membranes helps to generate 
a code of membrane identity that plays a fundamental role in 
orchestrating the processes occurring on such membranes. 
Some phosphoinositides (in particular phosphatidylinositol 
[PI] 4,5-bisphosphate [PtdIns(4,5)P2]) also act as precursors 
of other intracellular messenger molecules.
Among phosphoinositides, PI 4-phosphate (PtdIns4P) 
plays numerous fundamental roles. It has critical functions 
in the Golgi complex, the endosomal system, and the plasma 
membrane, which are mediated by its direct interaction with 
PtdIns4P-binding proteins (D’Angelo et al., 2008). Addi-
tionally, phosphorylation of PtdIns4P at the 5 position by 
type I PI monophosphate kinases (PIPKIs) represents the 
major pathway for the synthesis of PtdIns(4,5)P2 (Doughman 
et al., 2003), which, in turn, is the precursor of other impor-
tant signaling metabolites. PtdIns4P also has major regulatory 
actions on the localization and metabolism of other membrane 
lipids. For example, several oxysterol-binding protein–related 
proteins contain PtdIns4P binding sites that target them to 
PtdIns4P-containing membranes. One yeast oxysterol-binding 
Plasma membrane phosphatidylinositol (PI) 4-phos-phate (PtdIns4P) has critical functions via both di-rect interactions and metabolic conversion to PI 4, 
5-bisphosphate (PtdIns(4,5)P2) and other downstream 
metabolites. However, mechanisms that control this PtdIns4P 
pool in cells of higher eukaryotes remain elusive. PI4KIII, 
the enzyme thought to synthesize this PtdIns4P pool, is 
reported to localize in the ER, contrary to the plasma 
membrane localization of its yeast homologue, Stt4. In 
this paper, we show that PI4KIII was targeted to the 
plasma membrane as part of an evolutionarily conserved 
complex containing Efr3/rolling blackout, which we found 
was a palmitoylated peripheral membrane protein. PI4KIII 
knockout cells exhibited a profound reduction of plasma 
membrane PtdIns4P but surprisingly only a modest reduc-
tion of PtdIns(4,5)P2 because of robust up-regulation of 
PtdIns4P 5-kinases. In these cells, however, much of the 
PtdIns(4,5)P2 was localized intracellularly, rather than at 
the plasma membrane as in control cells, along with pro-
teins typically restricted to this membrane, revealing a 
major contribution of PI4KIII to the definition of plasma 
membrane identity.
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An issue of special interest is the link between the func-
tions of Stt4/PI4KIII and of Efr3 (Baird et al., 2008). Efr3 is 
the yeast homologue of Drosophila melanogaster rolling black-
out (RBO), a protein expressed at high levels in the nervous 
system of this organism whose mutation is responsible for a 
temperature-sensitive paralysis (Huang et al., 2004). RBO was 
proposed to be a transmembrane lipase, and its potential role in 
lipid metabolism was supported by changes in phosphoinositide 
and diacylglycerol levels in temperature-sensitive rbo mutants 
at the restrictive temperature (Huang et al., 2004).
Additional interest in the localization and properties of 
PI4KIII came from the recent identification by several groups 
of this enzyme as a critical host factor for the hepatitis C virus 
life cycle (Berger et al., 2009; Borawski et al., 2009; Tai et al., 
2009; Trotard et al., 2009; Alvisi et al., 2011), pointing to 
PI4KIII as to a potential target for anti–hepatitis C virus thera-
pies (Altan-Bonnet and Balla, 2012).
Collectively, these findings highlight the importance of 
addressing the still unclear and controversial subcellular local-
ization of PI4KIII and the function of the PtdIns4P pools regu-
lated by this enzyme. Here, we show recruitment of PI4KIII 
to the plasma membrane and show that its targeting requires 
presence in this membrane of EFR3/RBO, which we demon-
strate to be a palmitoylated peripheral scaffold protein, not a 
transmembrane lipase. We also show that loss of PI4KIII leads 
to a striking compensatory increase of PIPKIs that minimizes 
a global decrease in cellular levels of PtdIns(4,5)P2, in spite 
of the dramatic decrease of PtdIns4P. However, the bulk of 
PtdIns(4,5)P2 produced by this compensatory response is local-
ized not in the plasma membrane but, surprisingly, on intra-
cellular vesicles. Proteins and lipids normally segregated in the 
plasma membrane are also found on these vesicles, emphasiz-
ing how targeting of PI4KIII to the plasma membrane is a 
key upstream event in defining the proteomic and lipidomic 
identity of this membrane.
Results
Full-length PI4KIII visits the plasma 
membrane dynamically
In contrast to yeast Stt4, which is localized at the plasma mem-
brane (Audhya and Emr, 2002), a GFP-tagged PI4KIII con-
struct based on the published ORF (Nakagawa et al., 1996) 
displayed diffuse cytosolic localization with no discernable en-
richment on any cellular membrane (Fig. 1 A, left), as reported 
previously (Balla and Balla, 2006). We noted, however, that the 
mobility by SDS-PAGE of a construct corresponding to un-
tagged PI4KIII was slightly faster than the mobility of the en-
dogenous protein, as assessed by Western blotting (Fig. 1 B, 
compare first and third lanes). We thus considered the possi-
bility of an incorrect annotation and reexamined the reported 
translational start site of PI4KA (Nakagawa et al., 1996). An 
alignment of vertebrate PI4KA homologues (Fig. 1 C) revealed 
substantial conservation upstream of the reported translation 
start site (hence defined as M1*; Nakagawa et al., 1996), in-
cluding an additional conserved Met residue (defined as M1). 
Western blot analysis demonstrated that exogenously expressed 
protein–related protein (Osh4) was recently shown to bind 
either PtdIns4P or cholesterol via the same lipid-binding pocket 
and to exchange these two lipids on artificial membranes (Lehto 
et al., 2001; Raychaudhuri and Prinz, 2010; de Saint-Jean et al., 
2011). Finally, genetic and biochemical interactions between 
enzymes that control PtdIns4P levels (both PI 4-kinases and 
PI 4-phosphatases), and enzymes of the sphingolipid metabolic 
pathways have been reported (Tabuchi et al., 2006; Breslow 
et al., 2010).
In view of these considerations, and of numerous findings 
that link PtdIns4P, its downstream metabolites, and the lipids 
indirectly controlled by PtdIns4P to human disease (Vicinanza 
et al., 2008; McCrea and De Camilli, 2009), it is critically 
important to understand the mechanisms controlling PtdIns4P 
levels and metabolism on different membranes, in particular 
the plasma membrane, whose PtdIns4P pool serves as the 
precursor of the bulk of cellular PtdIns(4,5)P2. However, in-
formation on these mechanisms in metazoan cells is not as 
advanced as in yeast. The mammalian genome encodes four 
PI 4-kinase isoforms. PI4KIII and PI4KIII (encoded by 
PI4KA and PI4KB, respectively) are the homologues of the 
two major yeast PI 4-kinases, Stt4 and Pik1, which mediate 
PtdIns4P generation in the plasma membrane and Golgi com-
plex, respectively, in this organism (Audhya et al., 2000; Balla 
and Balla, 2006). PI4KII and PI4KII, two very similar pro-
teins encoded by PI4K2A and PI4K2B, respectively, repre-
sent a duplication of yeast Lsb6 and function in the Golgi 
complex, the endosomal system, and also to some extent at 
the plasma membrane (Balla and Balla, 2006).
In yeast, Stt4 has been shown to be localized at plasma 
membrane hotspots termed PI kinase (PIK) patches in a com-
plex with the accessory proteins Efr3 and Ypp1 (Baird et al., 
2008). Interestingly, considering that the bulk of the cortical ER 
is tightly apposed to the plasma membrane in this organism, 
Stt4 contains a so-called FFAT (two phenylalanines [FF] in an 
acidic tract) motif that enables binding to the integral ER mem-
brane proteins Scs2/22. In fact, contact sites between the ER 
and the plasma membrane serve as hubs controlling PtdIns4P 
metabolism in this organism (Stefan et al., 2011).
Although a pharmacological and knockdown study has 
suggested that, as in the case of yeast Stt4, PI4KIII functions 
in the generation of PtdIns4P at plasma membrane (Balla 
and Balla, 2006), surprisingly little is known about this enzyme. 
Based on immunofluorescence, a localization of PI4KIII in 
the ER has been reported (Wong et al., 1997), but such a local-
ization remains highly debated, in spite of the partial conser-
vation of its FFAT motif that would be expected to bind 
VAP-A/B, the mammalian Scs2/22 homologues. The exoge-
nous expression of tagged PI4KIII also failed to provide 
consistent results, and no evidence existed for its targeting 
to the plasma membrane (Balla and Balla, 2006). In mam-
malian cells, ER–plasma membrane contacts are much less 
extensive than in yeast, and the bulk of the ER is not local-
ized in close proximity to the plasma membrane. How the 
mechanisms of PtdIns4P generation have adjusted to the dif-
ferent architecture of cells of higher eukaryotes is an impor-
tant open question.
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the plasma membrane (Baird et al., 2008), our finding is con-
sistent with a role for PI4KIII at the plasma membrane. It was 
therefore of interest to determine how PI4KIII is recruited to 
the plasma membrane.
PI4KIII recruitment to the plasma 
membrane requires its interaction with 
EFR3 and TTC7
Immunoprecipitation (IP) of endogenous PI4KIII from mouse 
brain extracts, followed by mass spectrometry analysis, identi-
fied two interactors, EFR3B and TTC7B, that, interestingly, are 
the yeast homologues of Efr3 and Ypp1, the other constituents 
of yeast PIK patches (Fig. S1; Baird et al., 2008). The inter-
action of EFR3B and of TTC7B with PI4KIII was confirmed 
using IP followed by Western blotting with endogenous and 
exogenously expressed proteins (Fig. 2, A and B). To assess 
whether EFR3B and TTC7B have a role in PI4KIII recruit-
ment, we expressed tagged versions of these proteins and per-
formed knockdown experiments.
M1-PI4KIII co-migrated with endogenous PI4KIII, in 
contrast to the smaller M1*-PI4KIII (Fig. 1 B). Furthermore, 
determination of PI4KA translation initiation sites using ribo-
some footprinting after harringtonine treatment (Ingolia et al., 
2011) suggested that M1, but not M1*, was a strong transla-
tion start site (Fig. 1 D). This analysis also revealed a poten-
tial non-AUG start site (ACG, encoding Thr and indicated as 
T* in Fig. 1 D) between M1 and M1*.
We considered the possibility that an incorrectly assigned 
start site may have affected previous studies of PI4KIII and 
next investigated whether M1-PI4KIII had a different subcel-
lular localization than M1*-PI4KIII. The majority of GFP-
M1-PI4KIII fluorescence was still localized in the cytosol 
(Fig. 1 A, right). However, total internal reflection fluores-
cence (TIRF) microscopy revealed that GFP-M1-PI4KIII, 
but not GFP-M1*-PI4KIII, transiently visited the plasma 
membrane (Fig. 1 E and Video 1; also see Fig. 3). Although 
this dynamic behavior of PI4KIII appeared to differ from that 
of its yeast homologue, Stt4, which forms stable PIK patches at 
Figure 1. Full-length PI4KIII visits the plasma membrane dynamically. (A) Confocal imaging of HeLa cells transfected with GFP-M1*-PI4KIII (left) or 
GFP-M1-PI4KIII (right). (B) Anti-PI4KIII Western blot comparing electrophoretic mobility of endogenous (Endog.) PI4KIII and either exogenously ex-
pressed M1-PI4KIII or M1*-PI4KIII in lysates of HEK cells. Molecular masses are given in kilodaltons. (C) Alignment of the N-terminal region of vertebrate 
PI4KIII orthologues. The black shading denotes conservation of amino acid identity, and the gray shading denotes conservation of amino acid similarity. 
(D) Ribosome footprinting reveals M1 and T*, but not M1*, as likely PI4KIII translation start sites. The data shown were pooled from two biological replicate 
experiments. (E) TIRF microscopic analysis shows highly dynamic spots of GFP-M1-PI4KIII, but not of GFP-M1*-PI4KIII, at the plasma membrane, reveal-
ing very transient visits of the enzyme to this membrane. COS-7 cells were transfected with GFP-M1-PI4KIII (top row) or GFP-M1*-PI4KIII (bottom row) 
and imaged by TIRF microscopy, with a 1-s interval between each image acquisition. Bars: (A) 20 µm; (E) 2 µm.
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that PI4KIII, like its yeast homologue, is at least partially 
targeted to the plasma membrane and requires both EFR3 and 
TTC7 for efficient recruitment to this membrane.
EFR3 is a peripheral membrane protein 
whose N-terminal palmitoylation is 
essential for plasma membrane localization
To gain further understanding of the mechanisms that local-
ize PI4KIII to the plasma membrane, we investigated the 
membrane targeting of EFR3, as this protein is a necessary 
factor for recruiting both TTC7 and PI4KIII to this mem-
brane. At the molecular level, EFR3/RBO was proposed to 
function as an integral membrane lipase (Huang et al., 2004). 
Our bioinformatic analysis, however, predicted that none of 
the EFR3/RBO homologues from yeast to humans contains 
transmembrane regions and that the protein, instead, comprises 
multiple HEAT (Huntington, elongation factor 3, regulatory 
subunit A of protein phosphatase 2A, and target of rapamycin) 
repeats. Further sequence analysis identified a Cys-rich motif at the 
N terminus of EFR3 that is conserved in all metazoans and could 
potentially act as a palmitoylation site (Fig. 4 A). Accordingly, 
a bioorthogonal metabolic labeling approach (Hang et al., 2011) 
Individually, TTC7B was localized in the cytosol, whereas 
EFR3B was found constitutively at the plasma membrane 
(Fig. 2 C). Coexpression of GFP-M1-PI4KIII with EFR3B 
and TTC7B resulted in significant colocalization of all three 
proteins at the plasma membrane (Fig. 2 D). Control experi-
ments demonstrated that although EFR3B could recruit TTC7B 
to the plasma membrane (Fig. 2 E), EFR3B alone was not suffi-
cient to recruit GFP-M1-PI4KIII to this membrane (Fig. 2 F). 
We note that the stable association of a large fraction of the cel-
lular GFP-M1-PI4KIII pool with the plasma membrane when 
it is cooverexpressed with TTC7B and EFR3B stands in con-
trast the puncta observed by TIRF microscopy in cells express-
ing only GFP-M1-PI4KIII (Fig. 1 E). Thus, most likely, when 
M1-PI4KIII is overexpressed alone, its predominant local-
ization in the cytosol as well as its dynamic behavior at the 
plasma membrane (Fig. 1 E) are explained by limiting amounts 
of endogenous EFR3B and TTC7B at the plasma membrane. 
Consistent with this possibility, siRNA-mediated knockdown 
of EFR3B (and its close homologue EFR3A) and/or TTC7B 
(and its close homologue TTC7A) resulted in a striking reduc-
tion of the dynamic GFP-M1-PI4KIII puncta at the plasma 
membrane (Fig. 3). Collectively, these experiments demonstrate 
Figure 2. PI4KIII, EFR3B, and TTC7B form a complex at the plasma membrane. (A) Western blot analysis of anti-EFR3B and control immunoprecipitates 
from mouse brain homogenates. (B) Western blot analysis of anti-GFP, anti-HA, and anti-FLAG immunoprecipitates from lysates of HeLa cells transfected 
with GFP-M1-PI4KIII, EFR3B-HA, and TTC7B-FLAG. (C) Confocal imaging of live HeLa cells transfected with TTC7B-GFP (top) or EFR3B-tdTomato (bottom). 
(D) Imaging analysis of HeLa cells triple transfected with GFP-M1-PI4KIII, TTC7B-mCherry, and EFR3B-HA. EFR3B-HA immunofluorescence was performed 
with an anti-HA antibody followed by an Alexa Fluor 647–conjugated anti–rat secondary antibody. (E and F) Imaging analysis of HeLa cells double trans-
fected with EFR3B-HA and either TTC7B-mCherry (E) or GFP-M1-PI4KIII (F) after anti-HA immunofluorescence labeling. Insets show the region outlined with 
dotted lines at higher magnification. Bars: (full size images) 20 µm; (insets) 2 µm.
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that also harbored a Cre recombinase-estrogen receptor fusion 
transgene (Badea et al., 2003). Addition of (Z)-4-hydroxytamoxifen 
(4-OHT) to primary cultures of mouse embryonic fibroblasts 
(MEFs) derived from these mice induced gene recombination, 
leading to complete disappearance of PI4KIII within 10 d 
(Fig. 5 A) and a dramatic depletion of cellular PtdIns4P (to 25% 
of control cell levels; Figs. 5 B and S4).
The subcellular distribution of PtdIns4P in KO MEFs was 
probed via PtdIns4P biosensors that selectively bind to either the 
plasma membrane or the Golgi pool of this phosphoinositide 
(GFP-PHOsh2 [Balla et al., 2008] and GFP-GOLPH3 [Wood et al., 
2009], respectively). These experiments revealed a selective 
loss of plasma membrane PtdIns4P in KO MEFs (Fig. 5, D–F). 
The morphology of the Golgi complex was not affected (Fig. 5, 
F and G), in contrast to the dramatic changes in Golgi complex 
structure and function observed in cells lacking PI4KIII or 
PI4KII, two PI 4-kinases known to synthesize PtdIns4P in this 
region (Wang et al., 2003; Balla et al., 2005; Balla and Balla, 
2006). Additionally, no changes were observed in the levels of 
these other PI 4-kinases as well as of PI4KII, a further con-
firmation of the nonredundant functions of the PI 4-kinase iso-
forms (Fig. 5 A).
Consistent with a decrease of plasma membrane PtdIns4P 
and thus of a predicted decrease also of plasma membrane 
PtdIns(4,5)P2, a physiological phenomenon known to require 
the presence of these lipids in this membrane, namely the for-
mation of STIM1-dependent ER–plasma membrane contacts 
upon thapsigargin-induced depletion of intracellular Ca2+ stores 
(Korzeniowski et al., 2009; Walsh et al., 2010; Calloway et al., 
2011), was impaired (Fig. 6, A–D; and Videos 2 and 3). Rescue 
experiments to confirm the specificity of this phenotype were 
successful using GFP-M1-PI4KIII but not GFP-M1*-PI4KIII 
(Fig. 6, E–H; and Video 4), demonstrating that only GFP-
M1-PI4KIII is a fully functional protein.
Other PtdIns(4,5)P2-mediated processes occurring at the 
plasma membrane were clearly altered in PI4KIII KO MEFs. 
A drastic disruption of cortical actin, with a major loss of stress 
fibers, was observed, as assessed by phalloidin staining (Fig. 6 I). 
The organization of endocytic clathrin coat components was 
also affected. The normal fine puncta of immunoreactivity for 
the endocytic clathrin adaptors (and PtdIns(4,5)P2-binding pro-
teins) AP-2 and epsin 1, which represent clathrin-coated pits 
selectively localized at the plasma membrane, were replaced 
in PI4KIII KO MEFs by more coarse puncta (Fig. 6, J and K), 
many of which were localized on intracellular structures (also 
see Fig. 8 A). Further direct assessment of plasma membrane 
clathrin organization confirmed the abnormal size and distri-
bution of clathrin puncta in PI4KIII KO MEFs (Fig. S5 A). 
Additionally, most of these puncta were stable and did not 
turn over as in control MEFs, as visualized by TIRF micros-
copy (Fig. S5 B).
Ectopic PtdIns(4,5)P2 synthesis and 
localization in PI4KIII KO cells
Expression of RFP-PHPLC, a biosensor for PtdIns(4,5)P2, re-
vealed a robust reduction of PtdIns(4,5)P2 levels at the plasma 
membrane as expected (Fig. 7, A and B). Most surprisingly, 
revealed that FLAG-tagged EFR3A and EFR3B were palmi-
toylated at the N-terminal Cys-rich motif (Fig. 4 B). Impor-
tantly, palmitoylation-deficient mutants (C6S/C7S/C8S/C9S 
for EFR3A and C5S/C7S/C8S for EFR3B) were localized in 
the cytosol (Fig. 4 C), and the EFR3B palmitoylation-deficient 
mutant was unable to recruit tagged TTC7B and M1-PI4KIII 
to the plasma membrane (Fig. S2).
These data suggest that EFR3 is a peripheral membrane 
protein whose posttranslational lipidation enables its local-
ization to membranes and its function in PI4KIII-mediated 
PtdIns4P synthesis at the plasma membrane. Interestingly, 
the N-terminal Cys-rich motif is absent from yeast Efr3, in-
dicating that, in spite of the evolutionary conservation of the 
PI4KIII–EFR3–TTC7 complex, the mechanism that targets 
it to the plasma membrane is not conserved between yeast 
and higher eukaryotes.
Impact of the lack of PI4KIII on PtdIns4P and 
on PtdIns4P- and PtdIns(4,5)P2-dependent 
processes at the plasma membrane
To assess the precise contribution of PI4KIII to the plasma 
membrane pool of PtdIns4P and more generally the role of this 
enzyme in cell metabolism and physiology, a gene knockout 
(KO) approach was used. A conventional KO of mouse PI4KA, 
which encodes PI4KIII, resulted in early embryonic lethality 
(Fig. S3). Thus, we established a conditional PI4KA KO mouse 
Figure 3. Endogenous EFR3 and TTC7 are required for recruitment of 
GFP-M1-PI4KIII to the plasma membrane. HeLa cells were treated with a 
negative control siRNA or siRNA against EFR3A and EFR3B (siEFR3) and 
TTC7A and TTC7B (siTTC7) either alone or in combination. After 24 h, the 
cells were transfected with GFP-M1*-PI4KIII or GFP-M1-PI4KIII, and after 
an additional 24 h, the cells were imaged by TIRF microscopy, with a 1-s 
interval in between each image acquisition. (A) Representative images for 
each of the samples quantified in B. (B) Quantification of the number of 
GFP puncta observed at the plasma membrane, normalized per unit area. 
Error bars indicate standard deviations. *, P < 0.005 and **, P < 0.02, 
relative to GFP-M1-PI4KIII with control siRNA (n = 4–6). Bar, 5 µm.
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To test whether the mere loss of plasma membrane 
PtdIns(4,5)P2 in wild-type cells could cause a similar ectopic 
intracellular PtdIns(4,5)P2 phenotype, we acutely depleted this 
lipid from the plasma membrane of HeLa cells using a recently 
developed optogenetic approach (Idevall-Hagren et al., 2012). 
Although light-mediated recruitment of an inositol 5-phosphatase 
to the plasma membrane resulted in a rapid and massive loss 
of PtdIns(4,5)P2 in this membrane, as revealed by shedding 
of infrared RFP (iRFP)-PHPLC, no formation of intracellular 
PHPLC-positive vesicles was observed, even when the illumina-
tion was continually applied over a 1-h period (Fig. 7 G). To 
chronically prevent PtdIns(4,5)P2 accumulation at the plasma 
membrane, we expressed an inositol 5-phosphatase construct 
with a C-terminal CAAX motif that ensures constitutive plasma 
membrane targeting (Milosevic et al., 2005). Even 16 h after trans-
fection, no PtdIns(4,5)P2-positive intracellular vesicles similar 
to those found in PI4KIII KO MEFs were observed (Fig. 7 H), 
suggesting that more complex homeostatic mechanisms are 
involved in their formation.
Loss of plasma membrane identity in 
PI4KIII KO cells
Further characterization of the PtdIns(4,5)P2-positive intracel-
lular vesicles in PI4KIII KO MEFs revealed that they were 
positive for many proteins typically restricted to the plasma mem-
brane. For example, they were decorated by AP-2–, epsin-, and 
dynamin-positive puncta (Fig. 8 A). Dynamin was also localized 
however, global levels of cellular PtdIns(4,5)P2, as assessed 
biochemically, were only moderately reduced in KO MEFs (to 
80% of control cell levels; Fig. 5 C). A potential explanation 
for this modest change, which contrasts with the much stron-
ger reduction in global PtdIns4P levels (to 25% of control; 
Figs. 5 B and S4), in spite of the loss of PtdIns(4,5)P2 at the 
plasma membrane, came from a further analysis of the local-
ization of PtdIns(4,5)P2 and of the expression levels and local-
ization of PIPKIs (the enzymes that generate PtdIns(4,5)P2 
from PtdIns4P; Doughman et al., 2003) in PI4KIII KO cells. 
Although both PtdIns(4,5)P2, as detected by RFP-PHPLC, and 
exogenously expressed PIPKIs are typically segregated at the 
plasma membrane (Fairn et al., 2009), numerous vesicles that 
were highly heterogeneous in size and positive for RFP-PHPLC 
and for GFP-PIPKI were detected intracellularly in KO cells 
(Fig. 7, A [inset] and C). Furthermore, PIPKIs (PIPKI and 
PIPKI) were found to be massively up-regulated (Fig. 7 D), 
and numerous actin comets were observed in the cytoplasm 
(Fig. 7 E and Video 5), a known effect of the ectopic accumu-
lation of PtdIns(4,5)P2 on intracellular organelles (Rozelle et al., 
2000). Accordingly, PtdIns(4,5)P2-positive vesicles were de-
tected at the tip of comets (Fig. 7 F). Thus, loss of PI4KIII in 
MEFs leads to initiation of homeostatic mechanisms by which 
cells attempt to restore PtdIns(4,5)P2 levels through a more effi-
cient conversion of PtdIns4P to PtdIns(4,5)P2 in KO MEFs, but 
much of the PtdIns(4,5)P2 generated under such conditions is 
ectopically localized.
Figure 4. EFR3 is palmitoylated at a conserved 
N-terminal Cys-rich motif. (A) Alignment of N terminus of 
EFR3 orthologues in several species reveals a conserved 
Cys-rich motif. Red, Cys residues; blue, basic residues; 
green, hydrophobic residues. (B) EFR3A-FLAG and 
EFR3B-FLAG are palmitoylated at an N-terminal Cys-
rich motif. Recombinant EFR3A-FLAG (wild type [WT] 
or C6S/C7S/C8S/C9S quadruple mutant, denoted 
C6–9S) or EFR3B-FLAG (wild type or C5S/C7S/C8S tri-
ple mutant, denoted C5,7,8S) were immunoprecipitated 
from lysates of HeLa cells metabolically labeled with 
alkynyl palmitate (alk-16) or vehicle and transfected with 
the appropriate EFR3-FLAG construct. The samples were 
subsequently labeled with biotin-azide using click chem-
istry, treated with or without hydroxylamine (NH2OH) 
to cleave thioester linkages, and analyzed by West-
ern blotting, using streptavidin or anti-FLAG antibody. 
(C) Confocal imaging of live HeLa cells transfected with 
wild-type EFR3A-tdTomato, C6–9S EFR3A-tdTomato, or 
C5,7,8S EFR3B-tdTomato. Bars, 20 µm.
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in this membrane, and studies in both yeast and higher eukary-
otes had implicated Stt4/PI4KIII in its generation (Audhya 
 et al., 2000; Balla et al., 2005). However, the localization in cells 
of higher eukaryotes of this enzyme, which is expected to be of 
fundamental importance in cell physiology because its product is 
an essential precursor of key regulatory messenger molecules, 
had remained highly controversial (Balla and Balla, 2006). The 
prevailing view was that it was predominantly localized in the ER 
(e.g., Wong et al., 1997; Balla and Balla, 2006; Altan-Bonnet and 
Balla, 2012; Bianco et al., 2012), and no evidence has been re-
ported for its targeting to the plasma membrane.
Because of lack of suitable antibodies for the detection of 
the endogenous protein by immunocytochemistry (despite re-
peated attempts), the subcellular targeting of PI4KIII can only 
be explored by the expression of tagged PI4KIII. Here, we 
show that the failure of a previous study to reveal an association 
of PI4KIII with the plasma membrane is explained by the in-
correct identification of the N-terminal sequence of this enzyme 
(Balla and Balla, 2006). We demonstrate that EFR3/RBO and 
TTC7, the mammalian homologues of yeast Efr3 and Ypp1, 
play a key role in the recruitment of PI4KIII to the plasma 
membrane. As in yeast, EFR3 is constitutively localized at the 
plasma membrane, but it is not capable of recruiting PI4KIII 
in the absence of Ypp1/TTC7. TTC7 is a soluble protein that 
requires interaction with EFR3 for membrane recruitment and 
likely acts as a bridge between PI4KIII and EFR3.
on actin comet tails (Video 6), as previously shown in cells 
overexpressing PIPKI (Lee and De Camilli, 2002). In con-
trast, the PtdIns(4,5)P2-positive vesicles did not colocalize 
with early or late endosomal markers (EEA1, Rab5, Rab9, and 
the PtdIns3P biosensor FYVEHrs) or a Golgi/PtdIns4P marker 
(PHOSBP; Fig. 8 A). Additionally, integral and peripheral mem-
brane proteins normally selectively segregated at the plasma mem-
brane, including fluorescently tagged M1 muscarinic receptor 
(M1R-YFP; Wess et al., 2007) and myristoylated/palmitoylated 
Lck membrane anchor (L10-GFP; Fig. 7 H; Rodgers, 2002), were 
found at these intracellular sites (Fig. 8 B). Likewise, wild-type 
EFR3B partially relocalized to the intracellular structures positive 
for PtdIns(4,5)P2 (Fig. 8 B), suggesting a reciprocal requirement 
of both EFR3 and PI4KIII for correct targeting of the PI4KIII–
EFR3–TTC7 complex to the plasma membrane. Additionally, 
plasma membrane levels of cholesterol, a lipid normally concen-
trated in this membrane, were 20% lower in PI4KIII KO MEFs 
relative to controls, whereas intracellular levels were increased 
(Fig. 8 C). Thus, PI4KIII appears to be a critical determinant 
of the lipidomic and proteomic identity of the plasma membrane.
Discussion
This study provides answers to long-standing questions con-
cerning the generation of PtdIns4P at the plasma membrane. It 
has long been known that an important pool of PtdIns4P exists 
Figure 5. PI4KIII and PtdIns4P production. (A) West-
ern blot analysis of the four PI 4-kinase isoforms in ly-
sates from control (Ctrl) and PI4KIII KO MEFs. (B and C) 
Quantification of PtdIns4P and PtdIns(4,5)P2 (shown 
as a percentage of total inositol phospholipids, n = 3) 
in control and PI4KIII KO MEFs, respectively. *, P < 
0.0001. (D) Imaging of the plasma membrane PtdIns4P 
pool in control and PI4KIII KO MEFs using GFP-PHOsh2. 
(E) Quantification of the plasma membrane/cytosol 
(PM/cyt) GFP-PHOsh2 fluorescence ratio in D based on 
line scans (control, n = 29; KO, n = 30; *, P < 0.0001). 
(F) Imaging of the Golgi complex PtdIns4P pool in 
control and PI4KIII KO MEFs using GFP-GOLPH3. 
(G) Imaging of Golgi complex morphology in control and 
PI4KIII KO MEFs using anti-GM130 immunofluorescence. 
Error bars indicate standard deviations. Bars, 20 µm.
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PI4KIII and thus could mediate the association of a small 
PI4KIII pool with the ER via the mammalian Scs2/Scs22 
homologue VAP-B (Kaiser et al., 2005), although contacts 
between the cortical ER and the plasma membrane are less 
abundant and smaller in mammalian cells compared with in 
yeast. No evidence for a major association of PI4KIII with 
the ER was obtained in our study.
Importantly, our results shed new light on EFR3/RBO. 
They demonstrate that EFR3 is not a transmembrane lipase as 
originally proposed by a study in Drosophila (Huang et al., 
2004). First, improved structural predictions do not support the 
presence of transmembrane regions or of a lipase-type fold. In-
stead, our bioinformatic analysis predicts that EFR3 is a cyto-
solic protein consisting entirely of -helical HEAT repeats. 
Second, the protein is palmitoylated at a conserved Cys-rich 
motif at its N terminus, and mutation of the Cys residues in this 
motif abolishes the plasma membrane targeting of EFR3. Inter-
estingly, the palmitoylation motif is conserved in all metazoan 
EFR3 homologues but is absent from yeast Efr3, demonstrating 
a conservation of function in spite of potentially divergent 
membrane-targeting mechanisms. In view of this revised func-
tion of EFR3/RBO, it will be of interest to reassess and further 
In yeast, in which fluorescently tagged proteins were ex-
pressed under the regulation of the endogenous promoter (and 
thus at physiological levels), Stt4 was shown to be stably asso-
ciated with the plasma membrane at “PIK patches.” In our ex-
periments, the recruitment of transfected GFP-tagged PI4KIII 
to the plasma membrane was highly dynamic unless its binding 
partners EFR3B and TTC7B were also overexpressed, possibly 
reflecting its stoichiometric excess relative to EFR3 and TTC7 
when expressed alone. Whether endogenous PI4KIII, EFR3, 
and TTC7 form stable patches in mammalian cells remains an 
open question.
A large fraction of the ER is constitutively closely ap-
posed to the plasma membrane in yeast, and these contact 
sites play an important role in PtdIns4P metabolism, as the 
ER-localized PtdIns4P phosphatase Sac1 is thought to act in 
trans to dephosphorylate PtdIns4P in the plasma membrane 
(Stefan et al., 2011). Although the relationship between yeast 
PIK patches and ER–plasma membrane contact sites remains 
unclear (Baird et al., 2008), it is of interest that Stt4 contains 
an amino acid sequence matching the so-called FFAT motif, 
which enables binding of cytosolic proteins to the ER-resident 
proteins Scs2/Scs22. This motif is partially conserved in 
Figure 6. Loss of PI4KIII causes perturbations 
of PtdIns4P- and PtdIns(4,5)P2-dependent pro-
cesses at the plasma membrane. (A–H) Control 
(A and B) and PI4KIII KO MEFs (C–H) were 
transfected with STIM1-mRFP. For rescue experi-
ments, KO MEFs were transfected with GFP-M1*-
PI4KIII (E and F) or GFP-M1-PI4KIII (G and H). 
Plasma membrane–associated STIM1-mRFP fluor-
escence was imaged by TIRF microscopy before 
(Tg) or 8 min after (+Tg) the addition of 1 µm 
thapsigargin (Tg). (I) F-actin in control and PI4KIII 
KO MEFs as revealed by staining with fluorescently 
labeled phalloidin. (J and K) Altered assembly of 
the endocytic clathrin machinery in control and 
PI4KIII KO MEFs as assessed by immunofluores-
cence labeling of AP-2 (J) and epsin 1 (K). Insets 
show a representative region at higher magnifica-
tion. Bars: (A–H) 10 µm; (I–K, full size images) 
20 µm; (J and K, insets) 5 µm.
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provide conclusive evidence for a role of PI4KIII as a key 
contributor to plasma membrane PtdIns4P, as previously sug-
gested by pharmacological and knockdown studies (Balla et al., 
2005, 2008). Interestingly, in the absence of PI4KIII, cells 
investigate the mechanisms of the temperature-sensitive para-
lytic phenotype in Drosophila rbo mutants.
The association of PI4KIII with the plasma membrane 
that we show here and the results of our gene KO experiments 
Figure 7. Ectopic PtdIns(4,5)P2 localization and up-regulation of PIPKIs in PI4KIII KO MEFs. (A) Imaging of PtdIns(4,5)P2 distribution in control and PI4KIII 
KO MEFs using RFP-PHPLC. (inset) Note the presence of PtdIns(4,5)P2-positive vesicles only in KO MEFs. (B) Quantification of the plasma membrane/cytosol 
(PM/cyt) GFP-PHPLC fluorescence ratio in control and PI4KIII KO MEFs based on line scans (control, n = 22; KO, n = 23; *, P < 0.0001). (C) PIPKI and 
PtdIns(4,5)P2 colocalize on intracellular vesicles in cells lacking PI4KIII. PI4KIII KO MEFs were transfected with RFP-PHPLC and GFP-PIPKI87 and imaged 
by confocal microscopy. Insets show the region outlined with dotted lines at higher magnification. (D) Western blot analysis of PIPKI and PIPKI levels in 
control MEFs, PI4KIII KO MEFs, and PI4KIII KO MEFs transfected with GFP-M1-PI4KIII (KO + rescue). *, P < 0.0002 (n = 3); **, P < 0.003 (n = 3). 
rel., relative. (E) Actin comet tails in PI4KIII KO MEFs visualized by CHUtrophin-mCherry (a marker of F-actin). (F) Actin comet tail in PI4KIII KO MEFs double 
transfected with CHUtrophin-mCherry and GFP-PHPLC. Note the presence of a PtdIns(4,5)P2-positive vesicle at the head of the comet. (G) Acute, 488-nm light-
mediated depletion of plasma membrane PtdIns(4,5)P2 from HeLa cells (see Materials and methods for details) results in diffuse intracellular fluorescence of 
the PtdIns(4,5)P2 probe iRFP-PHPLC but no detectable PtdIns(4,5)P2-positive intracellular vesicles. (H) Chronic depletion of plasma membrane PtdIns(4,5)P2 
from HeLa cells by transfection with a membrane-anchored inositol 5-phosphatase (mRFP-IPP1-CAAX; see cell on the right) results in diffuse intracellular 
fluorescence of the PtdIns(4,5)P2 probe iRFP-PHPLC, but no PtdIns(4,5)P2-positive intracellular vesicles are apparent 16 h after transfection. Note that the 
myristoylated/palmitoylated plasma membrane marker L10-GFP is retained at the plasma membrane. Ctrl, control. Error bars indicate standard deviations. 
Bars: (A [inset], C [inset], E, and F) 5 µm; (H) 10 µm; (A [full size], C [full size], and G) 20 µm.
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Importantly and strikingly, the selective localization of 
specific intrinsic membrane proteins of the plasma membrane is 
disrupted by lack of PI4KIII. In PI4KIII KO MEFs, proteins 
normally segregated primarily in this membrane, including the 
M1 muscarinic receptor, a prototypical transmembrane protein 
(Wess et al., 2007), and the myristoylated/palmitoylated 
N-terminal anchor of Lck (Rodgers, 2002), were also found and 
enriched on PtdIns(4,5)P2-positive intracellular structures, which 
adopted a plasma membrane–like identity. Even EFR3, whose 
plasma membrane targeting is mediated by palmitoylation and 
thus at least partially via interactions with plasma membrane 
lipids (potentially cholesterol-enriched membrane rafts; Foster 
et al., 2003), localizes to such intracellular sites in PI4KIII KO 
MEFs, indicating that the unique protein composition of the 
plasma membrane relative to other membranes is perturbed. 
Effects produced by the deficiency of plasma membrane PtdIns4P 
on other lipids in this membrane, notably cholesterol, may con-
tribute to these changes. Thus, impairing the production of 
PtdIns4P at the plasma membrane drastically affects the proteomic 
and lipidomic composition of the plasma membrane, pointing 
to PI4KIII as a key upstream factor in determining the “identity” 
very strongly up-regulate the expression of PIPKIs, which 
convert PtdIns4P to PtdIns(4,5)P2, so that PtdIns(4,5)P2 levels 
are much less drastically decreased than PtdIns4P levels. The 
intracellular signaling pathways underlying this compensa-
tory change remain to be determined and represent an impor-
tant question to be addressed by future work. Additionally, 
PtdIns(4,5)P2, which is normally primarily concentrated at the 
plasma membrane, was surprisingly mislocalized on intracel-
lular structures in PI4KIII KO MEFs, leading to a partial relo-
cation onto these vesicles of actin regulatory proteins and 
endocytic proteins normally restricted to the plasma membrane. 
Because binding to PtdIns4P contributes to the membrane tar-
geting of PIPKIs (Kunz et al., 2002), PtdIns4P generated on en-
dosomes by type II PI 4-kinases (Balla and Balla, 2006) may 
play a role in the ectopic localization of the PIPKIs and may 
function as a substrate for PtdIns(4,5)P2 generation. Thus, it re-
mains possible that the very robust reduction in total PtdIns4P 
levels observed in PI4KIII KO MEFs may be caused not only 
by lack of PtdIns4P production at the plasma membrane but 
also by increased consumption of the PtdIns4P pool generated 
by type II PI 4-kinases.
Figure 8. Loss of plasma membrane identity in 
PI4KIII KO MEFs. Proteins typically restricted to 
the plasma membrane are found on intracellular 
PtdIns(4,5)P2-positive vesicles, which are negative 
for a variety of endosomal and Golgi markers. 
(A) PtdIns(4,5)P2-positive intracellular vesicles, vi-
sualized with GFP- or RFP-PHPLC, colocalize with 
endocytic clathrin machinery components (endog-
enous AP-2, epsin 1, and dynamin 2–GFP) but not 
with markers of endosomes (endogenous EEA1, 
GFP-Rab5, and GFP-Rab9), the endosomal phos-
phoinositide PtdIns3P (GFP-2×FYVEHrs), and Golgi-
localized PtdIns4P (GFP-PHOSBP). For clarity, PHPLC 
is false colored green, and the second marker is 
false colored red in all images. (B) Mislocaliza-
tion of plasma membrane proteins in cells lacking 
PI4KIII. PI4KIII KO MEFs were transfected with 
M1R-YFP, L10-GFP, or EFR3B-GFP and imaged by 
confocal microscopy. Note the accumulation of all 
markers in intracellular vesicles highlighted in the 
inset images. (C) Measurement of total and plasma 
membrane fraction of free cholesterol in control 
and PI4KIII KO MEFs. Total free cholesterol lev-
els were measured by HPLC, after lipid extraction, 
and normalized to total cellular phospholipid lev-
els. *, P < 0.0001 (n = 12 for control and KO). 
Plasma membrane free cholesterol was measured 
by treatment of cells with 10 mM MCD for 1 min 
followed by quantification of extracted cholesterol 
using an enzyme-coupled assay and normalization 
to total protein content. Error bars indicate stan-
dard deviations. *, P < 0.02 (n = 6 for control 
and KO). Bars: (A and B, insets) 5 µm; (B, full size 
images) 20 µm.
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C5,7,8S mutants of EFR3B-FLAG and EFR3B-tdTomato were generated using 
a mutagenesis kit (QuikChange II XL; Agilent Technologies). Human TTC7B 
(GenBank accession no. BC148529) was obtained from Thermo Fisher 
Scientific and cloned into the pEGFP-N1 vector using XhoI and SalI restric-
tion sites. TTC7B was subsequently subcloned into the pmCherry-N1 vector 
(Takara Bio Inc.) using a single digestion with XhoI (proper orientation was 
assessed using a test digestion with BamHI) and into the pcDNA3.0 vector 
(Invitrogen) with a C-terminal FLAG (DYKDDDDKI) tag incorporated into 
the antisense primers, using HindIII and XbaI restriction sites, to generate 
the TTC7B-FLAG construct.
Transfection and other reagents
MEFs were electroporated using the Amaxa Nucleofector method (Lonza), 
and HeLa and COS-7 cells were transfected with plasmids using transfection 
reagent (FuGENE HD; Promega) and with siRNA duplexes (obtained from 
Integrated DNA Technologies) using Lipofectamine RNAiMAX (Invitrogen).
Antibodies
Antibodies against mouse PI4KIII and EFR3B were generated by immuni-
zation of rabbits with the following constructs: PI4KIII, GST fusion to resi-
dues 1,021–1,207 (based on translation initiation at M1), and EFR3B, a 
keyhole limpet hemocyanin conjugate of the peptide Ac-TDEDRLSKRKSIGE-
TISLQVC-NH2 (Cocalico Biologicals, Inc.). Sera were affinity purified using 
the antigenic peptide immobilized on SulfoLink resin following the man-
ufacturer’s instructions (Thermo Fisher Scientific). A full list of antibodies 
used in this study appears in Table S1. All Western blots were developed 
by chemiluminescence using the SuperSignal West Pico, Femto, or Dura 
reagents (Thermo Fisher Scientific) unless otherwise noted. Sources of all 
antibodies used in this study are provided in Table S1.
Ribosome profiling to determine PI4KIII translation start sites
HEK 293 cells were treated for 90 s with 2 µg/ml harringtonine (LKT Labo-
ratories) to specifically immobilize initiating ribosomes while permitting 
runoff elongation. Cells were washed once in PBS and harvested in lysis 
buffer consisting of ribosome buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 
5 mM MgCl2, 1 mM DTT, and 100 µg/ml cycloheximide) with 0.5% Triton 
X-100. Cells were incubated for 10 min on ice and triturated, and the 
lysate was clarified by centrifugation. The clarified lysate was treated with 
2.5 U/µL RNase I (Ambion) for 45 min at room temperature, and ribo-
somes were harvested by ultracentrifugation (265,000 g for 4 h) through 
a 1-M sucrose cushion. RNA was extracted directly from ribosomal pellets 
and used to generate a deep sequencing library as previously described 
(Ingolia et al., 2011). Footprint sequencing libraries were analyzed on a 
sequencing system (HiSeq 2000; Illumina), and sequences were mapped 
to the human genome (hg19) using the TopHat short read aligner. Ribo-
some peptidyl site positions were identified as the location 12 nt (for 28- 
and 29-nt footprints) or 13 nt (for 30- and 31-nt footprints) downstream of 
the 5 end of the footprint (Ingolia et al., 2011).
TIRF microscopy
TIRF microscopy was performed at 37°C using an objective-type inverted 
microscope (IX-70; Olympus) fitted with a 60×, NA 1.45 TIRF microscopy 
lens (Olympus) and controlled by iQ software (Andor Technology). Laser 
lines (488 and 568 nm) from argon and argon/krypton lasers (CVI Melles 
Griot) were coupled to the TIRF microscopy condenser through a single op-
tical fiber. The calculated evanescent field depth was 100 nm. Cells were 
typically imaged without binning and with 0.2–0.5-s exposures and de-
tected with a back-illuminated electron-multiplying charge-coupled device 
camera (512 × 512 pixels; 16 bit; iXon 887; Andor Technology).
Spinning-disc confocal microscopy
All imaging experiments with the exception of TIRF microscopy were per-
formed on a spinning-disc confocal microscope, using the UltraVIEW VoX 
system (PerkinElmer) including an inverted microscope (Ti-E Eclipse; Nikon) 
equipped with Perfect Focus, temperature-controlled stage, 14-bit electron-
multiplying charge-coupled device camera (C9100-50; Hamamatsu Photon-
ics), and spinning disc-confocal scan head (CSU-X1; Yokogawa Corporation 
of America) controlled by Volocity software (PerkinElmer). All images were 
acquired through a 60 or 100× oil objective (1.4 NA, CFI Plan Apochro-
mat VC). Green fluorescence was excited with a 488-nm/50-mW diode 
laser (Coherent) and collected by a band pass (BP) 527/55-nm filter. Red 
fluorescence was excited with a 561-nm/50-mW diode laser (Cobolt) and 
collected by a BP 615/70-nm filter. Near-infrared fluorescence was excited 
with a 640-nm/50-mW diode laser (CVI Melles Griot) and collected by a 
BP 705/90-nm filter. Multicolor images were acquired sequentially.
of this membrane. We note that an independent study published 
just after our manuscript was submitted also reported that gen-
eration of PtdIns4P at the plasma membrane is a critical deter-
minant of the identity of this membrane and that loss of plasma 
membrane PtdIns4P is not matched by a corresponding reduc-
tion in PtdIns(4,5)P2 levels (some discrepancies between the 
two studies may depend upon the different experimental mod-
els; Hammond et al., 2012).
In conclusion, our study demonstrates that, in contrast 
to previous studies, at least a pool of PI4KIII is targeted to 
the plasma membrane. Furthermore, we provide mechanistic 
insight concerning the recruitment of PI4KIII to this mem-
brane and show that the PtdIns4P pool produced by this en-
zyme plays essential roles not only as a precursor to a variety 
of key regulatory metabolites but also, either directly or via 
its downstream metabolites, as a critical determinant of plasma 
membrane homeostasis and identity.
Materials and methods
Plasmids
The sources of cDNAs were as follows: STIM1-mRFP obtained from B. Baird 
(Cornell University, Ithaca, NY), GFP-PHOsh2 obtained from T. Balla (Na-
tional Institutes of Health, Bethesda, MD), GFP-GOLPH3 obtained from 
C. Burd (Yale University, New Haven, CT), CHUtrophin-mCherry obtained 
from W. Bement (University of Wisconsin-Madison, Madison, WI), GFP-
PHPLC obtained from A. De Matteis (Telethon Institute of Genetics and 
Medicine, Naples, Italy), RFP-PHPLC obtained from S. Grinstein (University 
of Toronto, Toronto, Ontario, Canada), M1R-YFP obtained from B. Hille 
(University of Washington, Seattle, WA), clathrin light chain-GFP obtained 
from J. Keen (Thomas Jefferson University, Philadelphia, PA), dynamin 
2–GFP obtained from M. McNiven (Mayo Clinic, Rochester, MN), GFP-
Rab9 obtained from S. Pfeffer (Stanford University, Stanford, CA), GFP-
2×FYVEHrs obtained from H. Stenmark (Oslo University, Oslo, Norway), 
and L10-GFP, GFP-PIPK187, iRFP-PHPLC, CIBN-CAAX, mCherry-CRY2-
5PtaseOCRL, mRFP-IPP1-CAAX, GFP-Rab5, and GFP-PHOSBP obtained from 
the De Camilli Laboratory.
M1*-PI4KIII and M1-PI4KIII were amplified by PCR from the 
following cDNA clones, respectively: NM_058004.1 (GenBank acces-
sion number; OriGene) and AB210002 (GenBank accession number; 
Kazusa DNA Research Institute) using the following primer pairs: M1*-
PI4KIII, 5-GCACAGAATTCGCCATGTGTCCAGTGGATTTCCATG-3 and 
5-GCACACTCGAGTCAGTAGGGGATGTCATTCTGA-3; and M1-PI4KIII, 
5-GCACAGAATTCATGGCGGCGGCCCCGGC-3 and 5-GCACACTC-
GAGTCAGTAGGGGATGTCATTCTGA-3. The PCR amplicons were cloned 
into pcDNA3.0 (Invitrogen) using EcoRI and XhoI cut sites. GFP-tagged 
constructs were generated by amplification from the appropriate original 
PI4KIII-containing vector and cloning into the pEGFP-C2 vector (Takara 
Bio Inc.) for GFP-M1-PI4KIII and the pEGFP-C1 vector (Takara Bio Inc.) 
for GFP-M1*-PI4KIII. We note that, during the course of our study, an 
NCBI revision of human PI4KA (available from GenBank under acces-
sion no. NM_058004.3) expanded the predicted ORF to include the se-
quence in between M1* and M1. EFR3B was amplified from mouse brain 
cDNA using the following primers: 5-GCTCGAGGCCACCATGTACG-
GTGTGTGTGGCTGC-3 and 5-CGAATTCGGTATACACACAGATCAG-
GAAACTTCATC-3. The PCR amplicon was digested with XhoI and EcoRI 
and cloned into the pEGFP-N1 vector (Takara Bio Inc.). EFR3B was subse-
quently subcloned into the ptdTomato-N1 vector (Takara Bio Inc.) using XhoI 
and EcoRI restriction sites to generate the EFR3B-tdTomato construct and 
into the pcDNA3.0 vector (Invitrogen) with C-terminal FLAG (DYKDDDDKI) 
or HA (YPYDVPDYA) tags incorporated into the antisense primers, using 
EcoRI and NotI restriction sites, to generate the EFR3B-FLAG and EFR3B-HA 
constructs. Mouse EFR3A (GenBank accession no. BC007482) was ob-
tained from Thermo Fisher Scientific and cloned into the ptdTomato-N1 
vector (Takara Bio Inc.) using XhoI and EcoRI restriction sites to obtain 
the EFR3A-tdTomato construct and into the pCDNA3.0 vector (Invitrogen) 
with a C-terminal FLAG (DYKDDDDKI) tag incorporated into the antisense 
primers, using EcoRI and NotI restriction sites, to generate the EFR3A-FLAG 
construct. The C6–9S mutants of EFR3A-FLAG and EFR3A-tdTomato and the 
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supplement. In this study, three different sets of control and KO cells were 
used interchangeably, as indicated in Table S2, and no differences were 
observed between sets of control/KO pairs in all assays in which multi-
ple sets were tested.
Quantification of phosphoinositide levels
For the quantification of PtdIns4P and PtdIns(4,5)P2 shown in Fig. 5, control 
and PI4KIII KO MEFs were metabolically labeled with [3H]myo-inositol for 
days 7–10 after treatment with 4-OHT (in the case of PI4KIII KO MEFs). 
Cells were lysed in 4.5% perchloric acid, and the pellet was rinsed three 
times with 0.1 M EDTA. The pellet was deacylated with a mixture of me-
thylamine/water/n-butanol/methanol (36:8:9:47) for 1 h at 50°C and 
dried in a SpeedVac (SVC 100; Savant), and the residue was extracted 
using 500 µl of a mixture of n-butanol/petroleum ether/ethyl formate 
(20:40:1) and 500 µl of water. The aqueous phase was resolved using 
anion-exchange HPLC with an ammonium phosphate gradient (LC-20AT ultra-
fast liquid chromatography [Shimadzu] equipped with a Partisil 5 SAX 4.6 × 
125–mm column [Whatman]) and identified using a radiometric detector 
(-RAM 4B; LabLogic). The identity of each peak was determined by com-
parison with known compounds, and the values reported in Fig. 5 are 
shown as the amount of the desired lipid as a percentage of total detect-
able inositol phospholipids (PtdIns, PtdIns4P, and PtdIns(4,5)P2). For the 
time course of phosphoinositide measurements shown in Fig. S4, total an-
ionic lipids were isolated by lysis in 1:1 methanol/aqueous 1 M HCl and 
2 mM AlCl3 followed by addition of chloroform, extraction of the organic 
layer with 1:1 methanol/2 mM oxalic acid, and evaporation of the sol-
vent. Deacylation was performed as described previously in this para-
graph, and the resultant glycerol-inositol phosphate peaks were analyzed 
by an HPLC system (Dionex; Thermo Fisher Scientific) equipped with a con-
ductivity detector (Nakatsu et al., 2010).
Acute depletion of PtdIns(4,5)P2 using an optogenetic approach
PtdIns(4,5)P2 was depleted from HeLa cells essentially as recently described 
(Idevall-Hagren et al., 2012). In brief, HeLa cells were transfected with 
CIBN-CAAX, mCherry-CRY2-5PtaseOCRL, and iRFP-PHPLC and kept in the 
dark before the experiment. PtdIns(4,5)P2 depletion was initiated by illumi-
nation with 488-nm light after a baseline image of the mCherry and iRFP 
channels was acquired. Constant PtdIns(4,5)P2 depletion was ensured by 
repeated 200-ms illuminations with 488-nm light at 1-min intervals for 1 h, 
whereas mCherry and iRFP images were acquired at 15-min intervals to 
minimize photobleaching.
Chronic depletion of PtdIns(4,5)P2
Chronic depletion of PtdIns(4,5)P2 was achieved by transfection of HeLa 
cells with a constitutively membrane-anchored 5-phosphatase (CAAX-
tagged catalytic domain of synaptojanin 1; Milosevic et al., 2005), iRFP-
PHPLC to monitor PtdIns(4,5)P2, and the myristoylated/palmitoylated 
anchor L10-GFP to monitor the plasma membrane. Images were acquired 
16 h after transfection by confocal microscopy.
Cholesterol measurements
Total free cholesterol was analyzed as described previously (Shui et al., 
2011). Only HPLC-grade solvents were used, and the deuterated choles-
terol standard (cholesterol-26,26,26,27,27,27-d6) was obtained from 
C/D/N Isotopes Inc. In brief, total cellular lipid extracts were dissolved in a 
1:1 mixture of chloroform/methanol, spiked with 2.5 µg/ml cholesterol-d6, 
and analyzed using an HPLC system (1100 Series; Agilent Technologies) 
coupled to a mass spectrometer (3200 QTRAP; Applied Biosystems). The 
multiple reaction monitoring transitions for endogenous cholesterol 
(369.4/161.0) and cholesterol-d6 (375.4/161.0) were monitored in posi-
tive atmospheric pressure chemical ionization mode. Measured cholesterol 
levels were first normalized to the cholesterol-d6 standard and finally pre-
sented relative to the measured phospholipid concentration to account for 
sample-to-sample variation. The values shown in Fig. 8 C represent the 
mean free cholesterol shown as a percentage of control cell levels. Error 
bars represent the standard deviation (n = 12 each for control and KO). 
Plasma membrane cholesterol levels were quantified by brief exposure of 
cells to methyl--cyclodextrin (MCD; Sigma-Aldrich) followed by measure-
ment of the amount of extracted cholesterol using an enzyme-coupled assay, 
normalizing to total protein content determined after cell lysis (Zidovetzki 
and Levitan, 2007). In brief, control and PI4KIII KO MEFs were rinsed 
three times with PBS and incubated with 10 mM MCD (in PBS) at room 
temperature for 1 min. The solution was then collected, and the concentra-
tion of free cholesterol was determined using the enzyme-coupled assay kit 
(Amplex Red; Invitrogen) according to the manufacturer’s instructions, 
IP experiments
For mouse brain IP experiments, mouse brain homogenates were gener-
ated by 50 pulses in a Dounce homogenizer of 20 frozen mouse 
brains thawed into IP lysis buffer (150 mM NaCl, 20 mM Tris, 1 mM 
EDTA, and 1% NP-40, pH 7.4, supplemented with an EDTA-free inhibi-
tor cocktail tablet [cOmplete; Roche]). The suspension was centrifuged 
at 16,000 g for 30 min. The supernatant was subjected to IP as de-
scribed in this paragraph. For IP experiments from transfected HeLa cells, 
HeLa cells were harvested 24 h after transfection with the appropriate 
combinations of GFP-M1-PI4KIII, TTC7B-FLAG, and EFR3B-HA, resus-
pended in IP lysis buffer, sonicated briefly, and centrifuged for 10 min at 
16,000 g. The supernatant was immunoprecipitated in IP lysis buffer by 
addition of the appropriate primary antibody (or no primary antibody as 
a negative control) and rocking for 1 h at 4°C followed by the addition of 
20 µl protein G–conjugated Sepharose (GE Healthcare) and an additional 
1-h incubation at 4°C, rocking. The resin was then isolated by centrifuga-
tion at 1,000 g, rinsed three times with IP lysis buffer, and analyzed either 
by SDS-PAGE or Western blotting. In the case of the PI4KIII IP, candidate 
bands were excised from the Coomassie-stained gel, and protein identifi-
cation by liquid chromatography–mass spectrometry was performed at the 
Keck Research Facility at Yale University.
Biochemical analysis of EFR3 palmitoylation
HeLa cells were transfected with the appropriate EFR3-FLAG construct 
using FuGENE HD, and palmitoylated proteins were labeled using the proto-
col of Yount et al. (2011). 5 h after transfection, the media were exchanged 
for media made with dialyzed serum that was supplemented with 10 µM 
alk-16 (17-octadecynoic acid; Cayman Chemicals), and the cells were 
incubated for an additional 18 h. The cells were then rinsed with PBS. 
Lysis, IP with M2 anti-FLAG–conjugated agarose (Sigma-Aldrich), and 
rinses were performed using alk-16 IP buffer (150 mM NaCl, 50 mM 
triethanolamine, and 1% Triton X-100, pH 7.4, supplemented with an 
EDTA-free protease inhibitor cocktail tablet [cOmplete]). After the rinses, 
the supernatant was aspirated, and biotin-azide (a gift from M. Boyce 
and C. Bertozzi, University of California, Berkeley, Berkeley, CA) was 
conjugated to the resin-bound EFR3-FLAG using copper-catalyzed click 
chemistry. Where indicated, an aliquot of this solution was incubated 
with 2.5% neutral hydroxylamine (NH2OH). The samples were then 
boiled and analyzed by Western blotting, detecting with an infrared 
imager (Odyssey; LI-COR Biosciences).
Generation of PI4KIII conditional KO mice
The PI4KA conditional targeting strategy flanked exons 48–52 with 
loxP sites and inserted a neomycin resistance gene flanked by flippase 
recognition target sites into intron 47 (Fig. S3). The targeting vector 
(Gene Dynamics) was electroporated into hybrid C57BL/6J-129S1/
Sv mouse embryonic stem cells (Yale Cancer Center Animal Genomics 
Shared Resource), and positive clones were identified by Southern blot-
ting (Gene Dynamics; Fig. S3). Targeted embryonic stem cells were 
injected into blastocysts of C57BL/6J mice and transferred to the uteri 
of pseudopregnant recipient females. Chimeric male offspring were 
subsequently crossed to a enhanced flippase recombinase-expressing 
deleter strain (B6.Cg-Tg(ACTFLPe)9205Dym/J; The Jackson Labora-
tory) to remove the neomycin resistance gene. Obtained conditional 
mutant mice were then crossed with either a -actin-Cre mouse (FVB/ 
N-Tg(ACTB-cre)2Mrt/J; The Jackson Laboratory) to delete the PI4KA gene 
ubiquitously or a strain expressing an Esr1-Cre fusion protein (B6;129-
Gt(ROSA)26Sortm1(cre/ERT)Nat/J; The Jackson Laboratory) to generate mu-
tants in which PI4KA gene ablation could be induced pharmacologically 
by the addition of 4-OHT. Animal care and use was performed in accor-
dance with our institutional guidelines. Genotyping of the mutant mice 
was performed by PCR using the following primers: wild-type allele, 
5-CCGCCAGACTGACTTTGGCATGTATG-3 and 5-CCAGCATGATG-
TTGCCATTGTGCCTG-3; KO allele, 5-GGATGCTGTGCAGCACCAC-
TCCCTC-3 and 5-GGCCTGTGTCCAACATGAGTGTAACCAG-3; and 
floxed allele, 5-GGCAGAGGCAGGTGAATCTCTGAGTTCAAG-3 and 
5-GCAAGGGAGCATCAGGCTCTGGC-3.
Generation of PI4KIII conditional KO MEFs
Primary MEFs were generated from embryonic day 15 to postnatal day 1 
from the appropriate strains. Some populations of MEFs were immortalized 
using the standard NIH 3T3 protocol (Ferguson et al., 2009). To generate 
cells lacking PI4KIII, recombination was induced by treatment of cells with 
0.3–1.5 µM 4-OHT for 24–36 h followed by replacement of the media and 
subsequent growth for a total period of 7–10 d. Cells were grown in DMEM 
containing glutamine, 10% fetal bovine serum, and 1% penicillin/streptomycin 
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Image analysis
Image analysis was performed using Volocity and ImageJ (National Insti-
tutes of Health). For the quantification of GFP-PHOsh2 and GFP-PHPLC, a 
ratio of plasma membrane to cytosolic signal (derived from a line scan) 
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In all cases throughout the paper, statistical significance was calculated 
using an unpaired two-tailed Student’s t test with unequal variance, and error 
bars represent standard deviation.
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KO MEFs. Video 6 shows localization of dynamin 2 on dynamic actin 
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